The difference between information and
expert, data-driven actionable intelligence

 

August 2017

Welcome to the August 2017 issue of CMC Market Outlook

This monthly e-newsletter provides valuable insights for both buyers and sellers of CMC drug development services. Our coverage will help you identify and understand market trends that will inform your strategic business perspective.

Enjoy the August issue!

The PharmSource Team

CMOs Must Embrace Flexible Manufacturing

by Jim Miller, President, PharmSource

The need for flexibility in manufacturing arrangements and technologies has never been greater. New products are more technically challenging, produced in smaller volumes, and subject to great market uncertainty stemming from competing therapies and reimbursement risk.

Contract development and manufacturing organizations (CDMOs) need to respond in both technical capabilities… read on


CDMOs Buttressed by Resilient Emerging Biopharma Sector

by Saul Richmond, Director of Market Intelligence

Publicly traded emerging biopharmaceutical companies increased their research and development (R&D) expenditure in the second quarter of 2017, reaching almost $3.9 billion, 45% greater than the spending level seen in the second quarter of 2015.

Although the total R&D expenditure of emerging biopharma companies (around $15 billion annually) is a fraction of the $100 billion spent by global bio/pharma companies (25 largest by revenue), it is overwhelmingly outsourced…read on


PharmSource President Jim Miller to Speak at Industry Event

Contract Pharma:
16th Annual Conference and Tabletop Exhibition.
New Brunswick
New Jersey
Thursday, September 14
2:15 pm


Dose CMOs Stuck in Idle

 

PharmSource’s just-released trend report, Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook – 2017 Edition, reveals several factors for the dose CMO industry’s relatively poor performance in 2016:

1. Rebound in drug development since 2013 is too recent to benefit dose CMOs

2. Heavy investment in captive capacity by global bio/pharma companies

3. Declining significance of dose manufacturing in drug cost of goods as new drugs with high value APIs dominate the pipeline

 


Save the date!

PBOA First Annual Meeting and Conference

October 3rd and 4th at the Bethesda North Marriott in Bethesda, MD

This event is open exclusively to PBOA-member companies!

Get the insider’s view on the regulatory, legislative and market trends driving the biopharmaceutical CDMO industry.

For details on the conference, visit www.pharma-bio.org/conference


PharmSource Strategic Advantage


Let PharmSource be your market intelligence guide.

PharmSource’s STRATEGIC ADVANTAGE service is the industry’s most respected outsourcing information web portal for serious consumers of information on contract drug development and manufacturing. Developed from PharmSource’s expert proprietary research, you won’t find this information in any other resource.

See for yourself how this resource gives you vital tools for understanding the industry.

To request a test-drive today, contact nathaniel@pharmsource.com / +1-703-383-4903, ext. 112.